| Identification | Back Directory | [Name]
1,3-bis(4-Bromophenyl)-5-phenyl-2,4-imidazolidinedione | [CAS]
878533-35-8 | [Synonyms]
CAY10508
1,3-bis(4-Bromophenyl)-5-phenyl-2,4-imidazolidinedione
2,4-Imidazolidinedione, 1,3-bis(4-bromophenyl)-5-phenyl- | [Molecular Formula]
C21H14Br2N2O2 | [MDL Number]
MFCD12912318 | [MOL File]
878533-35-8.mol | [Molecular Weight]
486.16 |
| Hazard Information | Back Directory | [Description]
Central cannabinoid (CB1) receptor antagonists and inverse agonists exhibit therapeutic potential for obesity and drug dependence, while being devoid of psychotropic effects. CAY10508 is a potent and selective central cannabinoid (CB1) receptor inverse agonist with a Ki value of 243 nM and an EC50 of 195 nM. A 10 μM concentration of CAY10508 resulted in 100% and 35% displacement of [3H]-CP-55,940 at the CB1 and peripheral cannabinoid (CB2) receptors, respectively. A [35S]-GTPγS binding assay revealed the inverse agonist properties of CAY10508 at the CB1 receptor. | [Uses]
1,3-Bis(4-bromophenyl)-5-phenyl-2,4-imidazolidinedione is a central cannabinoid (CB1) receptor antagonist and inverse agonist. It may be a potential therapeutic agent for treating obesity and drug dependence. | [Uses]
An imidazolidine-2,-4-dione derivative that is an effective and selective inverse agonist of CB cannabinoid receptor | [IC 50]
hCB1: 195 nM (EC50); hCB1: 243 nM (Ki) | [References]
[1] GIULIO G. MUCCIOLI. Synthesis and Activity of 1,3,5-Triphenylimidazolidine-2,4-diones and 1,3,5-Triphenyl-2-thioxoimidazolidin-4-ones: Characterization of New CB1 Cannabinoid Receptor Inverse Agonists/Antagonists[J]. Journal of Medicinal Chemistry, 2006, 49 3: 872-882. DOI: 10.1021/jm050484f |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|